

Intellego and Shanghai Zhongyou Medical High-Tech Co., Ltd (Likang) expands collaboration in new 360 million – 1,4 billion USD deal over five years in the Asian market, outside of China

Due to a positive reception on the dosimeter products, Intellego and Likang have agreed speed up the deliveries for the Chinese market but also to expand its collaboration to cover additional markets healthcare markets, outside of China. Intellego has granted the exclusive sales and marketing right for two UVC disinfection product used in the healthcare market in Japan, South Korea, Singapore, Thailand, Indonesia and Malaysia, which is connected to the minimum volumes of 360 million USD. The amount might be higher depending on which product mix that is sold.

The deal is dependent on market approval from regulatory agencies and other standard terms such as product quality. The parties do not foresee any significant regulatory obstacle as the product has a low-risk classification and majority of documentation is already in place. The volumes will be reached over a five-year time period with scaling volumes over time. Sales launch is expected to take place in 2025 which is when the first revenue from this project is expected."

Zhongyou Medical (Likang) is a wholly owned subsidiary of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd, which is listed on the Shenzhen Stock market, a leading distributor of a variety of disinfectant products into more than 3000 hospitals in China nationally.

Yuwell medical, with full name of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd. has established 12 R&D centers and 9 production bases in Shanghai, Shenzhen, Nanjing, Suzhou, Danyang, Tibet, the Netherlands, Germany, Italy, and other places, forming a complete global R&D, production, marketing, and service network that serves more than 300,000 medical institutions worldwide and covers 131 countries and regions, benefitting 300 million households around the world. <https://www.yuwell.com/>

Contacts

For further information, please contact:

Claes Lindahl, CEO Intellego Technologies AB

E-mail: claes.lindahl@intellego-technologies.com

Phone: +46 735 344 634

About Us

Intellego Technologies develops and manufactures color indicators that show the effect of irradiation with, among other things, invisible ultraviolet light, UV light. Color indicators are used globally in, for example, the disinfection industry, the sunscreen industry, and the manufacturing industry. Intellego's indicators have been developed from the company's patented photochromic ink, which can be adapted to different wavelengths of light and various application areas across a range of different industries. Intellego Technologies was founded in 2011, is headquartered in Stockholm, and is listed on the Nasdaq First North Growth Market.

The company's Certified Adviser on the Nasdaq First North Growth Market Stockholm is Mangold Fondkommission AB.

Intellego's website: <https://intellego-technologies.com/en/>

Subscribe to Intellego's press releases: <https://intellego-technologies.com/sv/pressmeddelanden/>

Contact the communications team: communications@intellego-technologies.com

This information is information that Intellego Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-21 11:01 CET.

Attachments

[Intellego and Shanghai Zhongyou Medical High-Tech Co., Ltd \(Likang\) expands collaboration in new 360 million – 1,4 billion USD deal over five years in the Asian market, outside of China](#)